(Alliance News) - GSK PLC on Thursday said it has expanded its shingles vaccine collaboration with Chongqing Zhifei Biological Products Ltd in China, including an extended term length.

UK pharma major GSK has into an agreement with Chongqing Zhifei Biological Products (Zhifei) to revize the terms on which ...

GSK (GSK) announced that it has entered into an agreement with Chongqing Zhifei Biological Products to revise the terms on which Zhifei will ...

GSK expands the licensing deal with Zhifei to market its shingles vaccine in China for an additional eight years till 2034.

GSK plc (GSK, GSK.L), on Thursday, said it has agreed with Chongqing Zhifei Biological Products Ltd. to revise the terms on which ...

Revised deal with Zhifei to manage near-term challenges GSK ... first time since 2021 5:13 PM UTC · Updated ago Reuters, the news and media division of Thomson Reuters, is the world’s largest ...

China's Zhifei will pay GSK about 2.3 billion pounds ($2.9 billion) for the exclusive rights to distribute GSK's shingles ...

GSK plc GSK announced that it has revised its collaboration deal with Chongqing Zhifei Biological Products (Zhifei), China's largest vaccine maker, to co-market its shingles vaccine Shingrix in ...

Drugmaker GSK has revised and extended its strategic vaccine collaboration with Chinese firm Chongqing Zhifei Biological Products.

GSK PLC extended its collaboration with Chongqing Zhifei Biological Products to commercialize its shingles vaccine Shingrix in China until 2034. The British pharma company said Thursday that it ...